Hepatocellular carcinoma (HCC) is the most common type of liver cancer and ranks among the leading causes of cancer-related deaths globally. Traditional treatment methods, including surgical resection, liver transplantation, and chemotherapy, often fall short in effectively managing HCC, highlighting the urgent need for novel therapeutic strategies. In recent years, antibody-based immunotherapy has gained traction as a promising approach in the fight against HCC. Significant advancements have been made in the development and clinical application of these therapies, particularly monoclonal antibodies that target immune checkpoints like PD-1 and CTLA-4, which have shown considerable efficacy in certain HCC patient populations. Furthermore, the development of cancer vaccines, such as those based on peptides, DNA, and dendritic cells, offers promising avenues for inducing targeted immune responses against HCC. Despite these advancements, challenges remain, including understanding resistance mechanisms and improving patient outcomes, necessitating further research and innovation in this field.
This research topic aims to provide a comprehensive overview of the recent progress in antibody-based immunotherapy for hepatocellular carcinoma, with a special focus on the development of cancer vaccines. The objective is to consolidate current knowledge, foster collaboration among researchers, and inspire further investigations that could lead to improved therapeutic outcomes for HCC patients. By addressing key questions and testing new hypotheses, this research topic seeks to advance the understanding and application of immunotherapy in HCC treatment.
To gather further insights in the realm of antibody-based immunotherapy for HCC, we welcome articles addressing, but not limited to, the following themes:
- Research on the use of antibody-based immunotherapies for HCC, including preclinical and clinical studies.
- Mechanistic insights into how antibody-based therapeutics work and factors contributing to therapy resistance.
- Exploration of novel targets and treatment strategies for antibody-based immunotherapy.
- Combination therapies involving antibodies and other treatment modalities.
- Advances in cancer vaccines for HCC, including antigen identification, vaccine design, and clinical trials.
- Biomarkers for patient selection and response prediction in antibody-based immunotherapy.
- Evaluation of safety profiles and management strategies for immune-related adverse events.
- Prospects and challenges in the field of antibody-based immunotherapy for HCC.
We warmly invite the submission of Original Research, Brief Research Reports, Reviews, and Mini-Reviews. Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Topic editor Anwaar Saeed reports a leadership role with Autem therapeutics, Exelixis, KAHR medical and Bristol-Myers Squibb; consulting or advisory board role with AstraZeneca, Bristol-Myers Squibb, Merck, Exelixis, Pfizer, Xilio therapeutics, Taiho, Amgen, Autem therapeutics, KAHR medical, and Daiichi Sankyo; institutional research funding from AstraZeneca, Bristol-Myers Squibb, Merck, Clovis, Exelixis, Actuate therapeutics, Incyte Corporation, Daiichi Sankyo, Five prime therapeutics, Amgen, Innovent biologics, Dragonfly therapeutics, Oxford Biotherapeutics, Arcus therapeutics, and KAHR medical; and participation as a data safety monitoring board chair for Arcus therapeutics. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and ranks among the leading causes of cancer-related deaths globally. Traditional treatment methods, including surgical resection, liver transplantation, and chemotherapy, often fall short in effectively managing HCC, highlighting the urgent need for novel therapeutic strategies. In recent years, antibody-based immunotherapy has gained traction as a promising approach in the fight against HCC. Significant advancements have been made in the development and clinical application of these therapies, particularly monoclonal antibodies that target immune checkpoints like PD-1 and CTLA-4, which have shown considerable efficacy in certain HCC patient populations. Furthermore, the development of cancer vaccines, such as those based on peptides, DNA, and dendritic cells, offers promising avenues for inducing targeted immune responses against HCC. Despite these advancements, challenges remain, including understanding resistance mechanisms and improving patient outcomes, necessitating further research and innovation in this field.
This research topic aims to provide a comprehensive overview of the recent progress in antibody-based immunotherapy for hepatocellular carcinoma, with a special focus on the development of cancer vaccines. The objective is to consolidate current knowledge, foster collaboration among researchers, and inspire further investigations that could lead to improved therapeutic outcomes for HCC patients. By addressing key questions and testing new hypotheses, this research topic seeks to advance the understanding and application of immunotherapy in HCC treatment.
To gather further insights in the realm of antibody-based immunotherapy for HCC, we welcome articles addressing, but not limited to, the following themes:
- Research on the use of antibody-based immunotherapies for HCC, including preclinical and clinical studies.
- Mechanistic insights into how antibody-based therapeutics work and factors contributing to therapy resistance.
- Exploration of novel targets and treatment strategies for antibody-based immunotherapy.
- Combination therapies involving antibodies and other treatment modalities.
- Advances in cancer vaccines for HCC, including antigen identification, vaccine design, and clinical trials.
- Biomarkers for patient selection and response prediction in antibody-based immunotherapy.
- Evaluation of safety profiles and management strategies for immune-related adverse events.
- Prospects and challenges in the field of antibody-based immunotherapy for HCC.
We warmly invite the submission of Original Research, Brief Research Reports, Reviews, and Mini-Reviews. Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Topic editor Anwaar Saeed reports a leadership role with Autem therapeutics, Exelixis, KAHR medical and Bristol-Myers Squibb; consulting or advisory board role with AstraZeneca, Bristol-Myers Squibb, Merck, Exelixis, Pfizer, Xilio therapeutics, Taiho, Amgen, Autem therapeutics, KAHR medical, and Daiichi Sankyo; institutional research funding from AstraZeneca, Bristol-Myers Squibb, Merck, Clovis, Exelixis, Actuate therapeutics, Incyte Corporation, Daiichi Sankyo, Five prime therapeutics, Amgen, Innovent biologics, Dragonfly therapeutics, Oxford Biotherapeutics, Arcus therapeutics, and KAHR medical; and participation as a data safety monitoring board chair for Arcus therapeutics. All other Topic Editors declare no competing interests with regards to the Research Topic subject.